The latest treatment advances for acute myelogenous leukemia.
The research into pathogenesis and mechanisms behind AML is advancing rapidly, but in general, translation into global application for the majority of patients is wanting. As more becomes known about the cytogenetic and molecular characteristics of leukemia cells and the pathways of leukemogenesis are further elucidated, it is hoped that future therapies will be directed more specifically toward the least toxic method to eradicate clonal malignant cells. HLA-haploidentical and alloBMT using KIR mismatch may dramatically improve survival for many more patients.
Adele R. Decof Cancer Center, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA. gcolvin@rwmc.org
Gerald A
GA
Colvin
Gerald J
GJ
Elfenbein
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000145:classification / Q000209:etiology / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction
D000970:Antineoplastic Agents